Breast Cancer Rates Lower With Less Hormone Ther... ( TUESDAY Nov. 30 (Heal...)

Breast Cancer Rates Lower With Less Hormone Therapy: Study

Date:11/30/2010

TUESDAY, Nov. 30 (HealthDay News) -- Reduced use of hormone replacement therapy (HRT) is linked to declines in rates of invasive breast cancer and ductal carcinoma in situ, the most common form of noninvasive breast cancer, a new study reports.

The University of California, San Francisco, study included nearly 700,000 women, aged 40 to 79, who underwent more than 2 million screening mammography examinations between January 1997 and December 2008.

Women aged 50 to 69 had the highest level of hormone therapy use and also had the largest reduction in invasive breast cancer when they stopped hormone therapy -- from 40 cancers per 10,000 mammograms in 2002 to 31 cancers in 2005, and 35 cancers in 2006, the investigators found.

The study also found a sharp drop in rates of ductal carcinoma in situ in this age group after they stopped using hormone therapy.

A parallel decrease in these types of breast cancer also occurred among women older than 70. However, there was no change in breast cancer rates during the study period among women aged 40 to 49, who were less likely to have been on hormone therapy.

The researchers said their findings suggest that hormone therapy helped promote breast cancer tumor growth.

"We show that the incidence of breast cancer decreases if you take the hormones away. The fact that we're continuing to see a decrease in invasive [breast] cancer means that the effects of stopping the hormones may be long-lasting," senior author Dr. Karla Kerlikowske said in a university news release.

The study was released online in advance of publication in an upcoming print issue of the Journal of Clinical Oncology.

More information

The U.S. National Cancer Institute has more about hormone replacement therapy and cancer.

-- Robert Pre
'/>"/>

1

GOOD

Page: 1 2
Related medicine news :

1. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
2. Low forms of cyclin E reduce breast cancer drugs effectiveness
3. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
4. For Some Breast Cancer Patients, Shorter Radiation Works Well
5. Short-term radiation therapy successful on breast cancer
6. Few Women at High Risk for Breast Cancer Take Tamoxifen
7. Hormone May Prevent Aggressive Breast Cancer
8. MSU researcher linking breast cancer patients with alternative therapies
9. MRI May Not Add Value to Routine Breast Cancer Care
10. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
11. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer

Post Your Comments:

Related Image:

Breast Cancer Rates Lower With Less Hormone Therapy: Study

(Date:5/23/2013)... high-risk neuroblastoma a common tumor that forms in the ... drugs. A study published by Cell Press in the ... reveals a new genomic approach to screen for compounds ... to differentiate, or convert from immature cells to more ... identified a compound that causes neuroblastoma cells to differentiate, ...

(Date:5/23/2013)... 2013 Sika Sarnafil , the ... today announced Imperial Roof Systems of Iowa as the ... dedication to quality during the re-roofing of the SuperTarget ... a Sika Sarnafil Elite contractor and one of Target’s ... is committed to sustainable building practices and they are ...

(Date:5/23/2013)... 23, 2013 Diabetes is one of ... become a nuisance when patients are unfortunate enough to ... the National Diabetes Information Clearinghouse at http://goo.gl/QyhCz , ... risk of developing neuropathy which further shrivels the nervous ... such patients. Such nerve damage affects the whole body ...

(Date:5/23/2013)... May 23, 2013 Professional Insurance Plans, ... the nation to celebrate Fibromyalgia Education and Awareness Month. ... chiropractors across the country, the agency feels that it ... of this syndrome that affects an estimated 10 million ... Association , the definition of Fibromyalgia (FM) is, “a ...

(Date:5/23/2013)... 2013 Retül University , the ... announce the formation of a strategic educational partnership with ... to offer a bike industry first “Positioned for Speed” ... for time trial, road and triathlon bike fit. , ... bike fitters with a Retül University, F.I.S.T. or S.I.C.I ...

Breaking Medicine News(10 mins):Health News:New screening approach uncovers potential alternative drug therapies for neuroblastoma 2 Health News:Sika Sarnafil Announces Recycling Project of the Year Winner 2 Health News:Neuropathy Nerve Damage Can Now Be Reversed With Neuracel 2 Health News:Professional Insurance Plans Encourages the Nation to Celebrate Fibromyalgia Education and Awareness Month 2 Health News:Retül, Ero Sports and Alphamantis Partner for Industry First Aero Fit Course 2 Health News:Retül, Ero Sports and Alphamantis Partner for Industry First Aero Fit Course 3

[0] New screening approach uncovers potential alternative drug therapies for neuroblastoma [0] Sika Sarnafil Announces Recycling Project of the Year Winner [0] Neuropathy Nerve Damage Can Now Be Reversed With Neuracel [0] Professional Insurance Plans Encourages the Nation to Celebrate Fibromyalgia Education and Awareness Month [0] Retül, Ero Sports and Alphamantis Partner for Industry First Aero Fit Course

... Mark,s Breathe Easy Tour, Inspires Those with Chronic Lung Disease to ... ... SAN DIEGO, July 24 SeQual Technologies Inc. (SeQual),announced today the ... the American Lung,Association of California and Seton Medical Center intended to ...

... PALO ALTO, Calif., July 24 Horizon Therapeutics, ... Timothy P.,Walbert has been named president, chief executive ... Horizon Therapeutics., "Tim has a long, proven ... the pain and arthritis areas," said George,Tidmarsh, M.D., ...

... Free Diabetes Education and Cholesterol ... Screenings to Race Spectators, INDIANAPOLIS, Ind., July ... and Polymer Technology Systems,Inc. as a partner in the recently announced ... as cholesterol,screenings at the IndyCar Series during the 2008 racing season., ...

... $0.51 from $0.38 in ... - Record diluted EPS increased 30.2 percent to $0.56 from $0.43 in, second-quarter 2007, excluding ... from the ... - Specialty revenues increased 32.6 percent to a record of nearly $2.0 ...

... Mass., July 24 Tepha, Inc., a developer ... resorbable polymers, announced,today that it has appointed John ... and Chief Operating Officer. Mr. Hartnett joins Tepha,following ... which he,progressed from field sales, to marketing management, ...

... BEIJING, July 24 /Xinhua-PRNewswire-FirstCall/ -- China Medical,Technologies, ... a leading China-based,medical device company that develops, ... high intensity focused ultrasound tumor,therapy systems, today ... results for the first quarter ended June ...

SeQual Technologies, American Lung Association of California and Seton Medical Center Partner to Support Survivor & Cyclist in 500-Mile California Ride Horizon Therapeutics Names Timothy P. Walbert as President and CEO Eli Lilly and Company and Vision Racing Sponsor Vision Wellness Tour at the IndyCar Series Across the Country Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance Tepha Announces Appointment of John Hartnett as Executive Vice President and Chief Operating Officer China Medical Technologies to Announce Financial Results for the First Quarter Ended June 30, 2008 on August 4, 2008

(Date:5/23/2013)... , May 23, 2013 Isis Pharmaceuticals, Inc. ... today announced that management will present a company overview at ... Conference on Thursday, May 30, 2013 at 8:40 a.m. ET ... live audio webcast of the presentation will be available on ... www.isispharm.com . A replay will be available on the ...

(Date:5/23/2013)... TUCSON, Ariz. , May 23, 2013 ... world,s first and only FDA, Health Canada and CE ... announced today that the Glasgow Science Centre in ... visitors annually, is featuring the SynCardia temporary Total ... as part of its $3 million Bodyworks Exhibition, one ...

(Date:5/23/2013)... , May 23, 2013 BioLife Solutions , ... proprietary clinical grade hypothermic storage and ... contract aseptic media manufacturer , today announced its ... Regenerative Medicine Congress 2013 this week in ... ) Dr. Aby J. Mathew, BioLife,s Senior ...

Breaking Medicine Technology:Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference 2 Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2 Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3 BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 2 BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 3

[0] Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference [0] Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition [0] BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress

... - Results Highlight the Potential of ... Algeta ASA (OSE: ALGETA), the ... BC1-04 study reported today it has completed its,comprehensive phase ... for bone metastases in patients with hormone-refractory,prostate cancer (HRPC). ...

... After eight weeks of treatment, RAD001 halted tumor growth ... with chemotherapy - Based on these promising data, Novartis ... advanced gastric cancer patients- Gastric cancer is the second ... of new cases occurring in East AsiaEAST HANOVER, N.J., ...

Cached Medicine Technology:Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 2 Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 3 Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 4 Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 5 Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 6 RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 2 RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 3 RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 4 RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 5 RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 6

Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

Medicine Products:

Morphine Quantitation, Serum or Plasma Monoethylglycinerylidide, Urine Moricizine (Ethmozine), Serum or Plasma Mono/Dizygotic Differentiation